文献速递肝病消化道肿瘤与早癌

MYC-PRMT5轴定义肝细胞癌的肿瘤发生与免疫应答

Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2021-07-13

本研究在DEN诱导的肝细胞特异性Myc敲除小鼠模型中发现,尿液对称二甲基精氨酸(SDMA)以MYC依赖方式升高,人HCC患者尿液SDMA也升高。机制上PRMT5为MYC直接靶基因,催化SDMA生成;PRMT5抑制剂GSK3326595可抑制MYC过表达转基因小鼠肝肿瘤生长,上调Cdkn1b/p27,诱导淋巴细胞浸润和MHC II类表达,与抗PD-1联用提高疗效。

要点

  • PRMT5是MYC的直接靶基因,催化SDMA生成,可作为MYC驱动HCC的代谢标志物。
  • PRMT5抑制剂GSK3326595通过上调p27抑制肿瘤增殖并增强抗肿瘤免疫。
  • GSK3326595联合抗PD-1免疫检查点治疗可提高HCC疗效。

核心结论

  • PRMT5是MYC的表观遗传执行者,抑制PRMT5可协同抑制增殖并增强抗肿瘤免疫,为MYC驱动HCC提供治疗策略。

研究设计与样本

  • 研究使用肝细胞特异性Myc敲除与对照小鼠,经二乙基亚硝胺诱导肝癌,并进行LC-MS代谢组学分析。
  • 分析人HCC患者尿液样本,并在MYC过表达转基因小鼠中评估PRMT5抑制剂GSK3326595的疗效。

主要发现

  • Myc敲除小鼠肝癌模型中尿液二甲基精氨酸尤其SDMA以MYC依赖方式升高,人HCC患者尿液SDMA也升高。
  • Prmt5在HCC中高度诱导,为MYC直接靶基因,其编码的PRMT5催化精氨酸生成SDMA。
  • GSK3326595抑制MYC过表达转基因小鼠肝肿瘤生长,通过上调Cdkn1b/p27发挥抗增殖活性。
  • GSK3326595诱导淋巴细胞浸润和MHC II类表达,可能增强抗肿瘤免疫应答。
  • GSK3326595联合抗PD-1免疫检查点治疗提高HCC疗效。

临床怎么用

  • 尿液SDMA可能作为MYC驱动HCC的无创监测标志物。
  • PRMT5抑制剂GSK3326595单药或联合抗PD-1可能用于MYC驱动HCC的治疗。
  • PRMT5抑制可能改善「免疫冷」肿瘤对免疫检查点治疗的抵抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HCC is a leading cause of cancer-related deaths globally with poor outcome and limited therapeutic options. Although the myelocytomatosis (MYC) oncogene is frequently dysregulated in HCC, it is thought to be undruggable. Thus, the current study aimed to identify the critical downstream metabolic network of MYC and develop therapies for MYC-driven HCC. APPROACH AND RESULTS: Liver cancer was induced in mice with hepatocyte-specific disruption of Myc and control mice by administration of diethylnitrosamine. Liquid chromatography coupled with mass spectrometry-based metabolomic analyses revealed that urinary dimethylarginine, especially symmetric dimethylarginine (SDMA), was increased in the HCC mouse model in an MYC-dependent manner. Analyses of human samples demonstrated a similar induction of SDMA in the urines from patients with HCC. Mechanistically, Prmt5, encoding protein arginine N-methyltransferase 5, which catalyzes SDMA formation from arginine, was highly induced in HCC and identified as a direct MYC target gene. Moreover, GSK3326595, a PRMT5 inhibitor, suppressed the growth of liver tumors in human MYC-overexpressing transgenic mice that spontaneously develop HCC. Inhibition of PRMT5 exhibited antiproliferative activity through up-regulation of the tumor suppressor gene Cdkn1b/p27, encoding cyclin-dependent kinase inhibitor 1B. In addition, GSK3326595 induced lymphocyte infiltration and major histocompatibility complex class II expression, which might contribute to the enhanced antitumor immune response. Combination of GSK3326595 with anti-programed cell death protein 1 (PD-1) immune checkpoint therapy (ICT) improved therapeutic efficacy in HCC. CONCLUSIONS: This study reveals that PRMT5 is an epigenetic executer of MYC, leading to repression of the transcriptional regulation of downstream genes that promote hepatocellular carcinogenesis, highlights a mechanism-based therapeutic strategy for MYC-driven HCC by PRMT5 inhibition through synergistically suppressed proliferation and enhanced antitumor immunity, and finally provides an opportunity to mitigate the resistance of "immune-cold" tumor to ICT.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Luo Y, Gao Y, Liu W, et al. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma. Hepatology. 2021. PMID: 33896016. doi:10.1002/hep.31864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。